Hyaluronic acid dermal filler Restylane Kysse has been approved by the US Food and Drug Administration (FDA) for lip augmentation and the correction of upper perioral rhytids.
While used widely in the UK, the FDA approval now means the product can be used for these indications in the US when it is launched at an appropriate time following the COVID-19 pandemic.
The product uses Galderma’s Optimal Balance Technology and has been demonstrated to last up to a year, with high levels of patient satisfaction.
Alisa Lask, general manager and vice president of the US aesthetic business at Galderma said, “Restylane Kysse offers key attributes both providers and their patients desire in a lip injection – high satisfaction, consistent results and a proven clinical-safety profile. We are confident that the product will become a leading lip filler in the dynamic US market.”
Katie Bennett, brand manager for Galderma UK added, “Kysse is extremely popular in the UK and is linked with nurse Julie Horne’s lip technique, as it integrates smoothly for beautiful results in moving planes.”